Medullary thyroid cancer: Medical management and follow-up

Current Treatment Options in Oncology

Volumn 6, Issue 4, 2005, Pages 339-346

  Traugott, Amber ^b   Moley, Jeffrey F ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

(3 IODOBENZYL)GUANIDINE I 131; 17 ALLYLAMINO 17 DEMETHOXYGELDANAMYCIN; ALPHA INTERFERON; ANTINEOPLASTIC AGENT; CALCITONIN; CARCINOEMBRYONIC ANTIGEN; CARCINOEMBRYONIC ANTIGEN MONOCLONAL ANTIBODY; CARCINOEMBRYONIC ANTIGEN MONOCLONAL ANTIBODY IN 111; CHOLECYSTOKININ B RECEPTOR; CISPLATIN; DACARBAZINE; DOXORUBICIN; FIBROBLAST GROWTH FACTOR 4; FLUORODEOXYGLUCOSE; FLUOROURACIL; IMATINIB; INDIUM 111; IODINE 123; IODINE 131; PD 173074; PENTAGASTRIN; PENTETREOTIDE IN 111; PROTEIN TYROSINE KINASE INHIBITOR; RADIOPHARMACEUTICAL AGENT; SOMATOSTATIN DERIVATIVE; SUCCIMER TC 99M; THALLIUM 201; TYROSINE KINASE RECEPTOR; UNCLASSIFIED DRUG; UNINDEXED DRUG; VINDESINE;

CANCER IMMUNOTHERAPY; CANCER LOCALIZATION; CHEMOEMBOLIZATION; COMPUTER ASSISTED TOMOGRAPHY; DIAGNOSTIC IMAGING; DIET; FOLLOW UP; GENE MUTATION; HUMAN; LIFESTYLE; LYMPH NODE DISSECTION; METASTASIS; MULTIPLE ENDOCRINE NEOPLASIA; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PATIENT MONITORING; POSITRON EMISSION TOMOGRAPHY; POSTOPERATIVE PERIOD; PROGNOSIS; RECURRENT CANCER; REVIEW; THYROID MEDULLARY CARCINOMA; THYROIDECTOMY; TREATMENT OUTCOME;

EID: 24044463845     PISSN: 15272729     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11864-005-0037-7     Document Type: Review

References (63)

1. Mulligan LM, Kwok JB, Healey CS, et al.: Germ-line mutations of the RET protooncogene in multiple endocrine neoplasia type 2A (MEN 2A). Nature 1993, 363:458-460.
2. Donis-Keller H, Dou S, Chi D, et al.: Mutations in the RET proto-oncogene are associated with MEN 2A and FMTC. Hum Mol Genet 1993, 2:851-856.
3. Moley JF, DeBenedetti MK: Patterns of nodal metastases in palpable medullary thyroid carcinoma: recommendations for extent of node dissection. Ann Surg 1999, 229:880-887.
4. Sizemore GW, Heath H III, Carney JA: Multiple endocrine neoplasia type 2. Clin Endocrinol Metab 1980, 9:299-315.
5. Modigliani E, Cohen P, Campos JM, et al.: Prognostic factors for survival and for biochemical cure in medullary thyroid carcinoma: results in 899 patients. Clin Endocrinol (Oxf) 1998, 48:265-273.
6. Kebebew E, Ituarte PHG, Siperstein AE, et al.: Medullary thyroid carcinoma: clinical characteristics, treatment, prognostic factors, and a comparison of staging systems. Cancer 2000, 88:1139-1148.
7. Gilliland FD, Hunt WC, Morris DM, et al.: Prognostic factors for thyroid carcinoma: a population-based study of 15,698 cases from the Surveillance, Epidemiology and End Results (SEER) program 1973 to 1991. Cancer 1997, 79:564-573.
8. Skinner MA, DeBenedetti MK, Moley JF, et al.: Medullary thyroid carcinoma in children with multiple endocrine neoplasia types 2A and 2B. J Pediatr Surg 1996, 31:177-181.
9. Samaan NA, Draznin MB, Halpin RE, et al.: Multiple endocrine syndrome type 2B in early childhood. Cancer 1991, 68:1832-1834.
10. Girelli ME, Dotto S, Nacamulli D, et al.: Prognostic value of early postoperative calcitonin level in medullary thyroid carcinoma. Tumori 1994, 80:113-117.
11. Fugazzola L, Pinchera A, Luchetti F, et al.: Disappearance rate of serum calcitonin after total thyroidectomy for medullary thyroid carcinoma. Int J Biol Markers 1994, 9:21-24.
12. Wells SA, Haagensen D, Linehan W, et al.: The detection of elevated plasma levels of Carcinoembryonic antigen in patients with suspected of established medullary thyroid carcinoma. Cancer 1978, 42:1498.
13. Busnardo B, Girelli ME, Simioni N, et al.: Nonparallel patterns of calcitonin and carcinoembryonic antigen levels in the follow-up of medullary thyroid carcinoma. Cancer 1984, 53:278.
14. Van Heerden J, Grant CS, Gharib H, et al.: Long-term course of patients with persistent hypercalcitoninemia after apparent curative primary surgery for medullary thyroid carcinoma. Ann Surg 1990, 212:395-401.
15. Normann T, Gautvik KM, Johannasen JV, et al.: Medullary carcinoma of the thyroid in Norway: clinical course and endocrinologic aspects. Acta Endocrinol (Copenh) 1976, 83:71-85.
16. O'Riordain DS, O'Brien T, Weaver AL, et al.: Medullary thyroid carcinoma in multiple endocrine neoplasia types 2A and 2B. Surgery 1994, 116:1017-1023.
17. De Groot JWB, Links TP, Jager PL, et al.: Impact of 18F-fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) in patients with biochemical evidence of recurrent or residual medullary thyroid cancer. Ann Surg Oncol 2004, 11:786-794.
18. Hoegerle S, Altehoefer C, Ghanem N, et al.: 18F-DOPA positron emission tomography for tumour detection in patients with medullary thyroid carcinoma and elevated calcitonin levels. Eur J Nucl Med 2001, 28:64-71.
19. Diehl M, Risse JH, Brandt-Mainz K, et al.: Fluorine-18 fluorodeoxyglucose positron emission tomography in medullary thyroid cancer: results of a multicentre study. Eur J Nucl Med 2001, 28:1671-1676.
20. Brandt-Mainz K, Mueller SP, Goerges R, et al.: The value of fluorine-18 fluorodeoxyglucose PET in patients with medullary thyroid cancer. Eur J Nucl Med 2000, 27:490-496.
21. Musholt TJ, Musholt PB, Dehdashti F, et al.: Evaluation of fluorodeoxyglucose-positron emission tomographic scanning and its association with glucose transporter expression in medullary thyroid carcinoma and pheochromocytoma: a clinical and molecular study. Surgery 1997, 122:1049-1061.
22. Szakall S, Esik O, Bajzik G, et al.: 18F-FDG PET detection of lymph node metastases in medullary thyroid carcinoma. J Nucl Med 2002, 43:66-71.
23. Gotthardt M, Battman A, Hoeffken H, et al.: 18F-fluoro-2-deoxy-D-glucose positron emission tomography, somatostatin receptor scintigraphy, and computed tomography in metastatic medullary thyroid carcinoma: a clinical study and an analysis of the literature. Nucl Med Commun 2004, 25:439-443.
24. Bigsby RJ, Lepp EK, Litwin DE, et al.: Technetium 99m pentavalent dimercaptosuccinic acid and thallium 201 in detecting recurrent medullary carcinoma of the thyroid. Can J Surg 1992, 35:388-392.
25. Koizumi M, Taguchi H, Goto M, et al.: Thallium-201 scintigraphy in the evaluation of thyroid nodules: a retrospective study of 246 cases. Ann Nucl Med 1993, 7:147-152.
26. Ohnishi T, Noguchi S, Murakami N, et al.: Detection of recurrent thyroid cancer: MR versus thallium-201 scintigraphy. Am J Neuroradiol 1993, 14:1051-1057.
27. Sinha PS, Beeby DI, Ryan P, et al.: An evaluation of thallium imaging for detection of carcinoma in clinically palpable solitary, nonfunctioning thyroid nodules. Thyroid 2001, 11:85-89.
28. Skowsky WR, Wilf LH: Iodine 131 metaiodobenzylguanidine scintigraphy of medullary carcinoma of the thyroid. South Med J 1991, 84:636-641. Erratum in South Med J 1991, 84:816,937.
29. Baudin E, Lumbroso J, Schlumberger M, et al.: Comparison of octreotide scintigraphy and conventional imaging in medullary thyroid carcinoma. J Nucl Med 1996, 37:912-916.
30. Frank-Raue K, Bihl H, Dorr U, et al.: Somatostatin receptor imaging in persistent medullary thyroid carcinoma. Clin Endocrinol (Oxf) 1995, 42:31-37.
31. Berna L, Chico A, Matias-Guiu X, et al.: Use of somatostatin analogue scintigraphy in the localization of recurrent medullary thyroid carcinoma. Eur J Nucl Med 1998, 25:1482-1488.
32. Adams S, Baum RP, Hertel A, et al.: Comparison of metabolic and receptor imaging in recurrent medullary thyroid carcinoma with histopathological findings. Eur J Nucl Med 1998, 25:1277-1283.
33. Parkkila S, Ahonen A, Torniainen P, et al.: Detection of cervical metastases of thyroid medullary carcinoma by MoAb anti-CEA scintigraphy and immunohistochemistry. Eur J Nucl Med 1995, 22:1064-1068.
34. Peltier P, Curtet C, Chatal JF, et al.: Radioimmunodetection of medullary thyroid cancer using a bispecific anti-CEA/anti-indium-DTPA antibody and an indium-111-labeled DTPA dimer. J Nucl Med 1993, 34:1267-1273.
35. Juweid M, Sharkey RM, Behr T, et al.: Improved detection of medullary thyroid cancer with radiolabeled antibodies to carcinoembryonic antigen. J Clin Oncol 1996, 14:1209-1217.
36. Manil L, Boudet F, Motte P, et al.: Positive anticalcitonin immunoscintigraphy in patients with medullary thyroid carcinoma. Cancer Res 1989, 49:5480-5485.
37. Behr TM, Jenner N, Behe M, et al.: Radiolabeled peptides for targeting cholecystolkinin-B/gastrin receptor-expressing tumors. J Nucl Med 1999, 40:1029-1044.
38. Kwekkeboom DJ, Bakker WH, Kooij PP, et al.: Cholecystokinin receptor imaging using octapeptide DTPA-CCK analogue in patients with medullary thyroid carcinoma. Eur J Nucl Med 2000, 27:1312-1317.
39. Tung WS, Vesely TM, Moley JF: Laparoscopic detection of hepatic metastases in patients with residual or recurrent medullary thyroid cancer. Surgery 1995, 118:1024-1029.
40. Cohen MS, DeBenedetti M, Moley JF: Laparoscopic liver evaluation for recurrent medullary thyroid carcinoma (Abs) Proceedings of the Society of Surgical Oncology. Los Angeles, CA, 2003.
41. Husain M, Alsever RN, Lock JP, et al.: Failure of medullary carcinoma of the thyroid to respond to doxorubicin therapy. Horm Res 1978, 9:22-25.
42. Scherubl H, Raue F, Ziegler R: Combination chemotherapy of advanced medullary and differentiated thyroid cancer: Phase II study. J Cancer Res Clin Oncol 1990, 116:21-23.
43. Orlandi F, Caraci P, Berruti A, et al.: Chemotherapy with dacarbazine and 5-fluorouracil in advanced medullary thyroid cancer. Ann Oncol 1994, 5:763-765.
44. Schlumberger M, Abdelmoumene N, Delisle MJ, et al.: Treatment of advanced medullary thyroid carcinoma with an alternating combination of 5FU-streptozocin and 5FU-dacarbazine. Br J Cancer 1995, 71:363-365.
45. Grohn P, Kumpulainen E, Jakobsson M: Response of medullary thyroid cancer to low-dose alpha-interferon therapy. Acta Oncol 1990, 29:950-951.
46. Kaczirek K, Schindl M, Weinhaeusel A, et al.: Cytotoxic activity of camptothecin and paclitaxel in newly established continuous human medullary thyroid carcinoma cell lines. J Clin Endocrinol Metab 2004, 89:2397-2401.
47. Mahler C, Verhelst J, de Longueville M, et al.: Long-term treatment of metastatic medullary thyroid carcinoma with the somatostatin analogue octreotide. Clin Endocrinol (Oxf) 1990, 33:261-269.
48. Smid WM, Dullaart RP: Octreotide for medullary thyroid carcinoma associated diarrhea. Neth J Med 1992, 40:240-243.
49. Vitale G, Tagliaferri P, Caraglia M, et al.: Slow release lanreotide in combination with interferon-alpha 2b in the treatment of symptomatic advanced medullary thyroid carcinoma. J Clin Endocrinol Metab 2000, 85:983-988.
50. Lupoli G, Cascone E, Arlotta F, et al.: Treatment of advanced medullary thyroid carcinoma with a combination of recombinant interferon alpha-2b octreotide. Cancer 1996, 78:1114-1118.
51. Juweid ME, Hajjar G, Swayne LC, et al.: Phase I/II trial of 131I-MN-14 F(ab)2 anticarcinoembryonic antigen monoclonal antibody in the treatment of patients with metastatic medullary thyroid carcinoma. Cancer 1999, 85:1828-1842.
52. Waldherr C, Schumacher T, Pless M, et al.: Radiopeptide transmitted internal irradiation of noniodophil thyroid cancer and conventionally untreatable medullary thyroid cancer using [90Y]-DOTA-D-Phe1-Tyr3-octreotide: a pilot study. Nucl Med Comm 2001, 22:673-678.
53. Bodei L, Handkiewicz-Junak D, Grana C, et al.: Receptor radionuclide therapy with 90Y-DOTATOC in patients with medullary thyroid carcinomas. Cancer Biother Radiopharm 2004, 19:65-71.
54. Kraeber-Bodere F, Saie-Maurel C, Campion L, et al.: Enhanced antitumor activity of combined pretargeted radioimmunotherapy and paclitaxel in medullary thyroid cancer xenograft. Mol Cancer Ther 2002, 1:267-274.
55. Brierley JD, Tsang RW. External radiation therapy in the treatment of thyroid malignancy. Endocrinol Metab Clin North Am 1996, 25:141-157.
56. Nguyen TD, Chassard JL, Lagarde P, et al.: Results of postoperative radiation therapy in medullary carcinoma of the thyroid: a retrospective study by the French Federation of Cancer Institutes: the Radiotherapy Cooperative Group. Radiother Oncol 1992, 23:1-5.
57. Samaan NA, Schultz PN, Hickey RC: Medullary thyroid carcinoma: prognosis of familial versus nonfamilial disease and the role of radiotherapy. Horm Metab Res Suppl 1989, 21:21-25.
58. Schott M, Feldkamp J, Klucken M, et al.: Calcitonin-specific antitumor immunity in medullary thyroid carcinoma following dendritic cell vaccination. Cancer Immunol Immunother 2002, 51:663-668.
59. Stift A, Sachet M, Yagubian R, et al.: Dendritic cell vaccination in medullary thyroid carcinoma. Clin Cancer Res 2004, 10:2944-2953.
60. Cohen MS, Hussain HB, Moley JF: Inhibition of medullary thyroid carcinoma cell proliferation and RET phosphorylation by tyrosine kinase inhibitors. Surgery 2002, 132:960-967.
61. Ezzat S, Huang P, Dackiw A, et al.: Dual inhibition of RET and FGFR4 restrains medullary thyroid cancer cell growth. Clin Cancer Res 2005, 11:1336-1341.
62. Cuccuru G, Lanzi C, Cassinelli G, et al.: Cellular effects and antitumor activity of RET inhibitor RPI-1 on MEN2A-associated medullary thyroid carcinoma. J Natl Cancer Inst 2004, 96:1006-1014.
63. Carlomagno F, Vitagliano D, Guida T, et al.: ZD6474, an orally available inhibitor of KDR tyrosine kinase activity, efficiently blocks oncogenic RET kinases. Cancer Res 2002, 62:7284-7290.